John Camm's guest appearances

John Camm

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Vascular Adviser Podcast

Tom Ford

Peter Block

Jennifer Mieres

Robert Schwartz

Keith Fox

Jeffrey Davis

Colin Berry

Michael Gibson

Stephen Nicholls

Paul Ridker

Allan Jaffe

Matthew Budoff

Deepak L. Bhatt

Robin Hofmann

David Wilbur

OwlTail

This podcast is a follow-up to Bayer’s symposium at EHRA 2022 ‘What if? Protecting your patients with AF from stroke, no matter their journey.’In this discussion, Professor John Camm and Professor Keith Fox provide further insight as to why patients with AF undergoing PCI need such close attention when choosing an antithrombotic regimen. They also explore additional considerations for the management of patients with AF undergoing elective PCI. Finally, the experts provide their perspectives on how patients with AF undergoing catheter ablation can be best protected from cardioembolic stroke.The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer.Further details:• Read the 2020 ESC guidelines for the management of atrial fibrillation here:https://academic.oup.com/eurheartj/article/42/5/373/5899003• The 2020 ESC guidelines for the management of acute coronary syndromes can be found here: https://academic.oup.com/eurheartj/article/42/14/1289/5898842• Find the 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guidelines for the management of patients with atrial fibrillation here:https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665• The EHRA practical guide on the use of NOACs in patients with atrial fibrillation can be accessed here: https://academic.oup.com/europace/article/23/10/1612/6247378• The papers for the trials investigating NOACs in patients with AF undergoing PCI can be found here for rivaroxaban (https://www.nejm.org/doi/full/10.1056/nejmoa1611594),apixaban (https://www.nejm.org/doi/full/10.1056/NEJMoa1817083), edoxaban(https://www.sciencedirect.com/science/article/abs/pii/S0140673619318720) and dabigatran (https://www.nejm.org/doi/full/10.1056/nejmoa1708454)• The findings from the Japanese study of rivaroxaban monotherapy versus rivaroxaban plus clopidogrel, the AFIRE trial, is available here:https://www.nejm.org/doi/full/10.1056/nejmoa1904143• Data from the COMPASS trial can be accessed here:https://www.nejm.org/doi/full/10.1056/nejmoa1709118• For anticoagulant dosing information, see the European labels for apixaban(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban(https://www.ema.europa.eu/documents/product-information/xarelto-epar-productinformation_en.pdf) and warfarin (https://www.medicines.org.uk/emc/product/3064/smpc)• For antiplatelet dosing information, see the European labels for clopidogrel(https://www.ema.europa.eu/en/documents/product-information/plavix-epar-productinformation_en.pdf), prasugrel (https://www.ema.europa.eu/en/documents/productinformation/efient-epar-product-information_en.pdf) and ticagrelor(https://www.ema.europa.eu/en/documents/product-information/brilique-epar-productinformation_en.pdf)• The European label for pantoprazole can be accessed here:https://www.ema.europa.eu/en/documents/product-information/pantoloc-control-eparproduct-information_en.pdfShow notes: MA-M_RIV-ALL-1173-1Recording: MA-M_RIV-ALL-1172-1

This podcast is a follow-up to Bayer’s symposium at EHRA 2022 ‘What if? Protecting your patients with AF from stroke, no matter their journey.’ In this discussion, Professor John Camm and Professor Keith Fox provide further insight as to why patients with AF undergoing PCI need such close attention when choosing an antithrombotic regimen. They also explore additional considerations for the management of patients with AF undergoing elective PCI. Finally, the experts provide their perspectives on how patients with AF undergoing catheter ablation can be best protected from cardioembolic stroke. The views and opinions expressed throughout this podcast are those of the speakers based on their expertise and do not necessarily reflect those of Bayer. Further details: • Read the 2020 ESC guidelines for the management of atrial fibrillation here: <a href="https://academic.oup.com/eurheartj/article/42/5/373/5899003" rel="nofollow" target="_blank">https://academic.oup.com/eurheartj/article/42/5/373/5899003</a> • The 2020 ESC guidelines for the management of acute coronary syndromes can be found here: <a href="https://academic.oup.com/eurheartj/article/42/14/1289/5898842" rel="nofollow" target="_blank">https://academic.oup.com/eurheartj/article/42/14/1289/5898842</a> • Find the 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guidelines for the management of patients with atrial fibrillation here: <a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665" rel="nofollow" target="_blank">https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665</a> • The EHRA practical guide on the use of NOACs in patients with atrial fibrillation can be accessed here: <a href="https://academic.oup.com/europace/article/23/10/1612/6247378" rel="nofollow" target="_blank">https://academic.oup.com/europace/article/23/10/1612/6247378</a> • The papers for the trials investigating NOACs in patients with AF undergoing PCI can be found here for rivaroxaban (<a href="https://www.nejm.org/doi/full/10.1056/nejmoa1611594" rel="nofollow" target="_blank">https://www.nejm.org/doi/full/10.1056/nejmoa1611594</a>), apixaban (<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1817083" rel="nofollow" target="_blank">https://www.nejm.org/doi/full/10.1056/NEJMoa1817083</a>), edoxaban (<a href="https://www.sciencedirect.com/science/article/abs/pii/S0140673619318720" rel="nofollow" target="_blank">https://www.sciencedirect.com/science/article/abs/pii/S0140673619318720</a>) and dabigatran (<a href="https://www.nejm.org/doi/full/10.1056/nejmoa1708454" rel="nofollow" target="_blank">https://www.nejm.org/doi/full/10.1056/nejmoa1708454</a>) • The findings from the Japanese study of rivaroxaban monotherapy versus rivaroxaban plus clopidogrel, the AFIRE trial, is available here: <a href="https://www.nejm.org/doi/full/10.1056/nejmoa1904143" rel="nofollow" target="_blank">https://www.nejm.org/doi/full/10.1056/nejmoa1904143</a> • Data from the COMPASS trial can be accessed here: <a href="https://www.nejm.org/doi/full/10.1056/nejmoa1709118" rel="nofollow" target="_blank">https://www.nejm.org/doi/full/10.1056/nejmoa1709118</a> • For anticoagulant dosing information, see the European labels for apixaban (<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-" rel="nofollow" target="_blank">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-</a> _Product_Information/human/002148/WC500107728.pdf), dabigatran (<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-" rel="nofollow" target="_blank">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-</a> _Product_Information/human/000829/WC500041059.pdf), edoxaban (<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-" rel="nofollow" target="_blank">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-</a> _Product_Information/human/002629/WC500189045.pdf), rivaroxaban (<a href="https://www.ema.europa.eu/documents/product-information/xarelto-epar-productinformation_en.pdf" rel="nofollow" target="_blank">https://www.ema.europa.eu/documents/product-information/xarelto-epar-productinformation_en.pdf</a>) and warfarin (<a href="https://www.medicines.org.uk/emc/product/3064/smpc" rel="nofollow" target="_blank">https://www.medicines.org.uk/emc/product/3064/smpc</a>) • For antiplatelet dosing information, see the European labels for clopidogrel (<a href="https://www.ema.europa.eu/en/documents/product-information/plavix-epar-productinformation_en.pdf" rel="nofollow" target="_blank">https://www.ema.europa.eu/en/documents/product-information/plavix-epar-productinformation_en.pdf</a>), prasugrel (<a href="https://www.ema.europa.eu/en/documents/productinformation/efient-epar-product-information_en.pdf" rel="nofollow" target="_blank">https://www.ema.europa.eu/en/documents/productinformation/efient-epar-product-information_en.pdf</a>) and ticagrelor (<a href="https://www.ema.europa.eu/en/documents/product-information/brilique-epar-productinformation_en.pdf" rel="nofollow" target="_blank">https://www.ema.europa.eu/en/documents/product-information/brilique-epar-productinformation_en.pdf</a>) • The European label for pantoprazole can be accessed here: <a href="https://www.ema.europa.eu/en/documents/product-information/pantoloc-control-eparproduct-information_en.pdf" rel="nofollow" target="_blank">https://www.ema.europa.eu/en/documents/product-information/pantoloc-control-eparproduct-information_en.pdf</a> Show notes: MA-M_RIV-ALL-1173-1 Recording: MA-M_RIV-ALL-1172-1

EHRA 2022 - Expert Podcast With John Camm And Keith Fox

Peter Smits

In this interview, John Camm and Pieter Smits discuss the Compare-Acute trial (Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD): fractional flow reserve-guided acute, complete revascularization versus culprit lesion-only treatment in patients presenting with ST-segment elevation myocardial infarction and multivessel disease.

In this interview, John Camm and Pieter Smits discuss the Compare-Acute trial (Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD): fractional flow reserve-guided acute, complete revascularization versus culprit lesion-only treatment in patients presenting with ST-segment elevation myocardial infarction and multivessel disease.

ACCEL Lite: Featured ACCEL interview with John Camm and Peter Smits